Elanco Animal Health Incorporated - Bayer Aktiengesellschaft’s animal health business

Acquirer(s)

  • Elanco Animal Health Incorporated

Target(s)

  • Bayer Aktiengesellschaft’s animal health business

Summary

Elanco Animal Health Incorporated proposes to acquire Bayer Aktiengesellschaft’s animal health business, which covers development and distribution of prescription and non-prescription products for farm and companion animals. In Australia, this includes:

  • pharmaceuticals, such as parasiticides and antimicrobials and analgesics,
  • specialty products, which include immunomodulators,
  • nutritionals, including vitamins, feed supplements and feed additives, and
  • other products including disinfectants.

Market definition

Refer to the attached Public Competition Assessment.

Competition analysis

Refer to the attached Public Competition Assessment.

Timeline

DateEvent
20/12/2019ACCC commenced informal review under the Informal Merger Review Process Guidelines.
03/02/2020Closing date for submissions from interested parties.
10/03/2020ACCC requested further information from the parties. Former provisional date for announcement of findings (12 March) delayed.
09/04/2020ACCC received further information from the parties.
22/04/2020ACCC is awaiting further information from the parties. Former provisional date for announcement of findings (30 April) is delayed.
29/05/2020ACCC commenced market consultation on proposed s87B undertaking. ACCC timeline recommenced.
10/06/2020Closing date for submissions relating to the draft proposed divestment undertaking.
15/06/2020ACCC is awaiting information from the parties. Former provisional date for announcement of findings (18 June) is delayed.
29/06/2020ACCC received further information from the parties.
09/07/2020ACCC announced it would not oppose the proposed acquisition, subject to a section 87B undertaking accepted by the ACCC.